The Not Mini Adults Podcast - “Pioneers for Children’s Healthcare and Wellbeing”
The Not Mini Adults Podcast - “Pioneers for Children’s Healthcare and Wellbeing”
Episode 43: 'Blood Brain Barrier' with Meritxell Teixidó
In this episode, we're joined by Dr. Meritxell Teixidó, CEO and co-founder of Gate2Brain, a Barcelona-based biotech company that is pioneering novel ways of delivering therapies across the blood-brain barrier. Meritxell shares the fascinating journey of how her team are using peptide-based technology to open up entirely new possibilities for treating brain disorders, including those that affect children.
It’s an inspiring conversation about science, perseverance, and the impact that bold ideas can have on the future of paediatric medicine.
Thinking of Oscar website and contact details can be found here.
Follow us on Twitter here or Instagram here.
Theme Music - ‘Mountain’
–
Copyright Lisa Fitzgibbon 2000
Written & performed by Lisa Fitzgibbon,
Violin Jane Griffiths
Podcast editing - Chris Robson Audio
Podcast artwork thanks to - The Podcast Design Experts
It's a technology that helps to cross the what is called the blood brain barrier, that is the barrier that protects the brain. Okay? That makes it very difficult that drugs reach the brain. But this isn't a general thing for all the diseases in the brain. So the technology is useful for that. Then in the kids, it's known that this barrier is more robust or tight. So it's even more difficult to cross. Why? Probably philosophically, I always explain the same. Probably because it's a brain that needs to be further protected when it's in development. And if it's not good, if it's not true, it will be good enough. Let's put it as a vision. I think it's probably nature decides to have a tired bio during the first years, and then when we get older, maybe it's not so real, it's important. It's always a bad uh barrier, but not so tight as when we are really, really small kids.
SPEAKER_00:Hello and welcome to the Not Many Adults Podcast, Pioneers for Children's Health and Wellbeing. My name is David Cole, and together with my wife Hannah, we are the founders of UK Children's Charity Thinking of Oscar. The mission of the charity is to bring the future of healthcare to children. And during this podcast, we talk to individuals and organisations that are doing just that. We are excited to bring to you the fifth season of the Not Mini Adult Podcast, and we have some fantastic guests coming up. In today's episode, we are joined by Dr. Mary Textel Texedo, CEO and founder of Gate to Brain, a Barcelona-based biotech company that is pioneering novel ways of delivering therapies across the blood-brain barrier. Mary shares the fascinating journey of how her team are using peptide-based technology to open up entirely new possibilities for treating brain disorders, starting with those affecting children. It's an inspiring conversation about science, perseverance, and the impact that bold ideas can have on the future of pediatric medicine. I hope you enjoy listening as much as we enjoy talking to Mary. Mary, hello. Thank you so much for joining us on the Not Mini Adults podcast. We're thrilled to be starting our fifth season with you and thrilled to be talking to you. When we first met uh maybe last year in Barcelona, I was intrigued and really excited about the work that you're doing. So uh thank you so much for joining us.
SPEAKER_01:No, pleasure is mine to really join this mini adults or not mini adults podcast, which is a lovely name for this mission of showing that they're not mini adults also.
SPEAKER_00:Thank you. Well, and I know uh having uh listened to you and um listened to you on some of the talks that you've you know done online or already that uh that we believe in very similar things in terms of um you know not enough funding going to children, not enough focus going on children, and and we're we'll come to that in terms of the uh the work that you're doing. But maybe we could start. Could you tell us a bit about um tell us a bit about yourself and uh and and how you got to be working in in children's health?
SPEAKER_01:Um I'm a chemist from background. I study here in Barcelona and decided that science is one of my uh things that I love to do. And so I established my group here in Barcelona, discovering how peptides that are very small proteins can help drugs reach the brain. So are these shuttles to the brain or bus to the brain? And that they can carry drugs that cannot reach the brain alone. But this is a very general technology, no. So during those 15 years, um, we started a collaboration with the Pediatric Hospital here in Barcelona, and because we were looking for one specific case where we can really use the technology and make a huge impact. So this was my entering to the paediatric health system because we discovered that there were these paediatric brain tumors that can benefit from the technology if we work hard for almost a decade. Let's put it like this.
SPEAKER_00:And uh and from that, you have uh formed an organization and you're uh now taking that uh or or working to take that to market. Talk to us a bit about Gate to Brain.
SPEAKER_01:Okay. So in 2020, no, when we were locked down at home doing caro cakes, um, there were four people, crazy people, that decided to um to create a novel company that is called Gate to Brain. So it's not like this. In fact, two years before that, we applied to an investment from Fundación Botin, that is um the foundation of one of the biggest banks in in Spain for sure, Banco Santander. We applied for that in 2018. And then in April 2020, they say, okay, you are the selected one. We were like, God, okay. Um we don't we didn't do adapt a single second. Say, okay, we are the selected ones, let's do it. Um so why I say let's do it, because that minute I leave my permanent position and jump to the creation of the company. Um, we are four founders, um, three female and one male. Um it doesn't start with a personal experience in our case, it starts, but it's true that we have a special sensitivity for kids. No, among the four of us, we have three kids, two kids, two kids, and I have one that administratively counts for three because it's a special kit, no? So um, so there was this special thing, but we don't we didn't adapt to say, okay, it's it's it's the moment. Let's do it. Let's do it. I'm so happy about that that jump because it was the way to advance the technology and be a bit more close to a reality of reaching first a clinical trial, and if it goes well, then a therapy, I always say in a decade.
SPEAKER_02:And what was it about the children's health that made you want to resolve that particular problem?
SPEAKER_01:So in our case, let's come from the more impactful part to the more pragmatic part, okay? Um, so our technology is a technology that helps to cross the what is called the blood-brain barrier, that is the barrier that protects the brain, okay? That makes it very difficult that drugs reach the brain. But this isn't a general thing for all the diseases in the brain. So the technology is useful for that. Then in the kids, it's known that this barrier is more robust or tight. So it's even more difficult to cross. Why? Probably philosophically, I always explain the same. Probably because it's a brain that needs to be further protected when it's in development. And if it's not good, if it's not true, it will be good enough. Let's put it as a vision. I think it's probably nature decides to have a tired bio during the first years, and then when we get older, maybe it's not so real, it's important. It's always a bad uh uh barrier, but not so tight as when we are really, really small kids. So then for us to validate the technology was the perfect scenario. Nobody will doubt that if we fail, we are able to bring a drug to the brain, it's because our technology has helped on that. It's not because the barrier was half open. No, no, no, no. It will be like uh the perfect scenario. This is one thing. Then the impact, obviously, we wanted to go, we decided the four founders, we wanted to go for an a mednit. And then I think that's not more. Um I think my pitches as a CEO of and CSO of Gate to Brain always start with the with this sentence. Children represent 25% of our actual population, 200 or no, 100% of our future if we don't decide to live 200 years, which is not my plan. Okay, so I start like this, no, because it's it's true, no, like in I would say in 100 years, only some of our kids will be there if we are lucky. So none of us. Um that's why we start in kids. So there were more biological reasons, but there are a lot of impact, um yeah, many things on the way.
SPEAKER_00:But if you can, but I I think this is something that we talk about a lot, and and I feel like it's more anecdotal actually in many respects, and there's a there's a theory if we can if we can solve things in children, then uh it's much easier to to solve to adults. But you have, I think, found a really um the the best use case because absolutely there is a physiological difference, and there is a it's as you say, more difficult to um uh to to to to work with children in this area. If you can solve this, moving into the adults into the adult area where uh arguably there is more money, more support, all the rest of it. Um, but you prove and help everybody else prove that actually starting in children is uh is a brilliant way to actually bring new therapeutics, new drugs to the market.
SPEAKER_01:We always claim that we are paediatic first, that doesn't mean paediatic only. So it's not that we are dealing with a solution that it's only for kids. I cannot imagine one solution, but yes, probably we will find solution that it's only for a disease that only happens when you are a kid, that will be a paediatic only solution. In our case, it's more of a paediatic first because it has some advantage. One thing is the impact of the decision, but then there's these biological reasons, and even there's so now that we are three years from a clinical trial, so in that specific tumor, we will be a first line. This means that the population of our clinical trial will be much more homogeneous if that if we go to an adult disease where maybe it will be a third line, and then the patients will come from treatments, previous treatments, so it will be more less homogeneous. So even the results that we can imagine from the clinical trial are much robust in terms of pragmatic of the of the data. And then everyone can imagine that jumping from kids to adults is not that probably not immediately, but nobody imagines that a drug that has been demonstrated that it's efficace and non-toxic for a kid will have a big, big problem on jumping to an adult population. The opposite sometimes happens, no? We adapt, uh no, we we develop for adults and then readapt somehow to kids, and then toxicity appears or efficacy.
SPEAKER_02:I you made the point that I was just uh getting interested in my head, is that you started in the hardest place in many senses, because um the the uh uh introducing something new into children is is almost scarier, is my perception from the from a non-medical person to introducing something new for adults. So are there extra barriers you had to um manage with uh as you were working through the clinical trials?
SPEAKER_01:Sometimes challenges also came together with opportunities, no, because um in regulatory, there are more we to be fair, the drug we are transporting, not the technology, but the drug that we are carrying has already been in kits, but in tumors that are outside the brain. So it's not we need to do all the development years, mice, pigs, whatever. So all the development, but in terms of regulatory, it's not putting that drug, the drug, not the technology, the drug for the first time in a kit. Okay, because if not the barrier will be extremely. Um having said that, yes, it was a it was uh it's a it's a brave decision, but it also gives um opportunities. For example, we have been able to attract 4.5 million euros in non-dilutive grants from national and international, um, like the European Commission. And one of the things that value is that really this thing of okay, children are the future, so we need to maybe not invest, but maybe because it's not investment, are grants, but to put money on that health of children. And I think that we are seeing a revolution on that. And I think that the podcast and everyone from families, um, medical doctors, associations, everyone is pushing on the same direction, and we will see a change in the next 10 years, probably.
SPEAKER_00:And and uh well, let's hope so, absolutely. And I think it's uh um it's a great again, kind of um advocate for for what we're put what we're all trying to do. Talk to us a bit about the brain, uh, the blood brain barrier. What does that uh what does that mean in in to uh to non-medical uh professionals or to people?
SPEAKER_01:So um the blood brain barrier is it's format at the level of the capillaries. So the capillaries of our body are formed by cells that form the walls of this capillary. And in all the capillaries, these cells have some small gaps between the cells. So the compounds that go on the blood can go to the tissue around the capillary, entering the cell of the capillary and going out at the other side, or they can go through these small gaps between the cells. This is the normal capillary. In the brain, these capillary have really tight junctions. So the compounds can only go from the blood to the brain parenchyma or brain tissue, entering the cell of the capillary and going out at the other side. And this is the blood-brain barrier, okay? The fact that to go from the blood to the brain, compounds need to enter the cell of the capillary and go out at the other side. This seems that it's very difficult, and it's very, very difficult. But really, these cells also have some doors that we scientists call transport mechanisms to allow, for example, the nutrients that the brain needs go from the blood to the brain, no, as a nutrient and any residue or can go on the other way and remove it from the brain. So, our peptides, the peptides we discovered, use these transdoors or transport mechanisms to squeeze there and cross from the blood to the brain, not affecting the normal functioning of that door, but just being able to go there. And not only go there, but carry together as a shuttle and or a car and caravan. I always play as a caravan and caravan, so as a caravan, bringing the drug to the brain. Okay. And that's the blood brain barrier, that's the technology of gate to brain on a nutshell.
SPEAKER_00:Where did it what I know you you talked a little bit about kind of you know where you started in terms of your uh interest in chemistry and everything, but when did you when did you discover or or decide that actually this was a viable thing? Or what was it that led to you kind of thinking that this would be something that would be uh worth you know your spending your career on?
SPEAKER_01:Yeah, so first is no, it's when we had the idea um that maybe peptides can be this tool, okay, um it was a bit inspired in nature, okay? I will explain you like a small story that, okay. So in the venom of venous animals, we don't use venous animals, okay, but in the venom of venous animals, there are thousands of peptides. Some of them reach the CNS of the animal that that venous animal attacks. Some of these peptides reach the CNS or the brain of that animal by crossing the blood brain barrier without destroying the blood brain barrier.
unknown:Okay.
SPEAKER_01:So there's a group of people studying these peptides to see which part of the peptide is the shuttle model, which part of the peptide was the toxic thing. So when you study this transport model, you can eliminate the toxicity bar, study that during some years. And then we discover miniapamine 4. So miniapamine 4 is a small peptide that we prepare chemically that comes from a peptide, or it's inspired in a peptide that it's found in the Bbenon. We don't use B's or B venon, okay? But as one time more, uh nature sometimes is the inspiration for medicines, many times, okay? Um, and then we prepare this and we prepare, so we prepare it in a bigger scale, and then this peptide is the one that we attach to the drug we want to transport.
unknown:Okay.
SPEAKER_01:Peptides for the general public are small molecules, uh, as small and small and small proteins. There are many peptides that are well known, such as for example, oxytocin, it's one peptide that is the one that induces the birth, the delivery in the birth. So natural products that we have all around us.
SPEAKER_02:And then you took you had your own learning through your career, and then as you said, you came into COVID, and at and at that time the you discovered you were awarded the funding. Um and so together with your colleagues, you took the plunge, and then clinical trials were starting. How how's that journey progressed since? How are the clinical trials going?
SPEAKER_01:Well, when we started the company, we were um just starting the mice thing, okay. And in these four or five years, um, we are now at the edge between rodents and non-rodents. We know that the non-rodance will be mini pigs, which a mini pig, it's it's not mini, it's 35 kilos of a pig, okay, because it's a pig, it's a very big animal, so mini peaks are 35 kilos of pig. So somehow, I'm always made, I love to make jokes. Somehow the mini peaks are close to our the weight of our patients in the clinical trial, okay? 35 kilos. So, but we are three years from the first real patient uh on the clinical trial. So we are not in the clinical trial yet, but we are on this important edge between jumping from the rodents to the non-rodance that we have validated that is the mini peak, the relevant species for our studies.
SPEAKER_00:And we I I always think with these things, what would you need to speed this up? You know, for me, you're what you're trying to do, there must be unfortunately lots of parents out there, lots of children out there that would obviously benefit from this straight away. Um and you as parents, you always think, How can we get this quicker? What would it enable you to get this quicker? You know, how can we do that?
SPEAKER_01:I think that um redirecing that the health of children is important is one of the ways that then it makes that um public money is devoted to to grants for research in this field. This is one approach. I will bet that it's important that um BCs or that there's uh some kind of regulation that investors always devote one part of the investments to impact things. And we maybe it's the moment to create a seal, no? You cannot claim you are an impact fan if you don't devote 5%, 2% of your fund to really things that maybe are not mainstream. This can be a way. And then um but I think that the families, the role of the families, it goes a bit beyond not only finding money. Um it's nice to not the actual families. I think that the actual families we need to protect them because probably they are going through the most difficult moment in their life for sure. Okay, so we are always protecting the actual families, but sometimes there are families that want to keep helping on that path that has been the difficult moment in their life, but they want to make a change. And sometimes they can help small companies such as get to brain in in giving opinion on things that we are designed. We are designing a clinical trial with all the team in the hospital, but having the voice of the families is relevant of what was important or what have been done, what needs to be done differently. Maybe an international family will prefer to have all the all the proofs or all the tests the same day because they are traveling back and forth. So I think to have these things or this vision of the families is important, um, not only in the finding money, okay? And that's always I say when some families approach us, it's like, okay, we don't have the product yet. Um we are working hard. Um we will do our best, but you can help us in many other things, not only in finding money, you can help us individualize that it's relevant for the society and that will start triggering many other things. And I really believe that um because if not, um breaking the taboo of childhood health, no? I think there's almost almost a taboo, eh? Like people say, no, children are not get not sick, no children get sick. I promise you. Apart from the natural things when you have a small kid, children also get sick, and then you need to visualize that that we need to fight for that or work for that. I prefer work that not fight. So, yes, we enroll, for example, in our case in the external advisory board of Gate to Brain, we have one family, we have two persons related to the paediatric brain tumor we are dealing with. Uh, Gloria, that she was mom of a girl with our tumor many years ago. She's giving her opinion, which is great. And then um Ricard that he was he was he had a brother with our tumor. So he's giving the opinion of a sibling of a brother, that it's a different opinion than mom and papa. Maybe what Ricard said that he had preferred he understood perfectly the fight they were going through or the moment, but they're like, okay, my opinion as a small kid that was close by, it's a different opinion, which is uh it's a lovely opinion, also. So you can give a lot of things to the to the companies that are doing this path to approach children uh or children's health.
SPEAKER_02:The journey that you're on with um Gate to Brain is obviously many years behind you and in front of you as well as you work through the different stages that you were describing. Um, but the the the question that I started to think about was uh are there other breakthroughs that you can anticipate on the far, far horizon that that are also you know drawing you and and motivating you in your work? So I think that really there are two things.
SPEAKER_01:One is that if no, if the product works for this specific tumor, I think that the jump to other brain tumors or even tumors in the retina, because there's in the same manner that there's the blood brain barrier, there's the blood retinal barrier, okay, that it's very similar. So maybe the product by itself can impact in other tumors, in children and adults. But then, because if we validate the technology, then probably the technology will be easier accepted to be incorporated in other drugs that need better transport. If you have one case that it works or that it's promising, it's easier that someone says, okay, why don't we try it for the gen therapy for other diseases? No, because you have one case where it has gone work. Um, so I think we are starting to see this movement. And then on the on the long run, um I would love to see the clinical trial. As a scientist, that I have been there from the very, very beginning, just drawing the molecule on a paper. Um to reach the mice was a big milestone. To reach a mini pig will be a bigger milestone, 35 kilos of milestone. But to be on a clinical trial, it's such a responsibility. But um, but I think that uh we will do it and let's let's think. I was saying we will move the science. This was our motto at the beginning. We will move the science as far as it wants to go. Maybe there will be one place that nowhere we will find a stop and say, oh, we cannot move it farther for whatever reason. But some uh science is uh it's a run by different pieces. Someone else will take it from this learning and bring it further. So even if we don't success until until until the end, uh we will do our part. And that's a bit our idea. And then if we really, really succeed and get to brain, get very famous, and I become very rich, which is very unrealistic. But okay, let's let's imagine we we have thought about what from the four founders, there are two of us that probably will create a foundation. It has even name, but I cannot, if I say the name, then I need to do a copyright. No, no, no, no, no, no. It's something like we are called Gate to Brain Medicines Beyond Barriers, uh, because it's these biological barriers, but also the barriers of the lack of development sometimes in pediatric, or the barriers of health for everyone everywhere. And probably we will create something like help beyond barriers. And we have starts our small things in that direction, which is a nice way. Every year, our we are 12 people, so we are not thousands, uh, 12 in three continents. So we are part of the team in Barcelona, Madrid, Granada, Tel Aviv, and Mumbai. Um we have three different religions, eight different languages, 35 years of difference between the youngest one and the oldest one. And I'm not the oldest one, okay? Um, and then we decide every year together, if we win any small prize and can be very, very small price, we decided to which initiative we give this award. And last year we decided because it needs to have, no, we put like, okay, it needs to go beyond barriers, different types of barriers. So last year we decided to sponsor a tuk-tuk in the middle of Mumbai, because there's a group of women in Mumbai that wanted to create a cooperative of tuktuks, tuktuks, these small taxis. And no, a tuktuk driver, a woman tuktuk driver in Mumbai is something that goes beyond any barrier that you imagine. So there must be one tuk tuk around there that it's sponsored by Bit2Brain, which is it's difficult to find because there are thousands of them, but uh probably one day I will find it.
SPEAKER_02:So it's that's absolutely brilliant. So I mean you're talking there about the collaboration amongst the team, but I had a question about collaboration because you talked very early on about the collaboration with the children's hospital and then with when you were looking for funding. And how important has the role of partnerships and collaborations been with you throughout the journey?
SPEAKER_01:I think it is it's very, very relevant, okay, because um all the actors should be there: the small companies, the investors, the families, the hospitals, but also the industry, the big the big companies, no? And and the movement is being there, okay. So we are starting a collaborative to have connections with companies that are opening childhood cancer programs in their pipeline. And it's not about social responsibility only. It's really in their pipeline. So it if there this is something that we cannot imagine 10 years ago, that we're like, oh, nobody cares. No, no, it's not nobody cares. Let's let's move it. At the end, it happens. And and we are starting to have these conversations and connections with those big pharma that are starting to see that there's a path also in childhood health.
SPEAKER_02:That's very encouraging.
SPEAKER_01:Let's see. Let's see how it evolves.
SPEAKER_00:Uh, but uh on uh to Hannah's point though, talk to us a little about um the work that you've done with the children's hospital. I think there's a lot of organizations that are trying to do um you know wonderful things in children's health, and they come up with funding, is obviously a big barrier, but but also you know, they want to work with and and learn from uh hospitals. And you talk about the um the system that you have in Barcelona, and you know, I've been fortunate enough to visit the hospital. I'm uh going in the not too distant future again. So talk to us about the relationship that you have with that and how that's helped.
SPEAKER_01:So we are a spin-off of the hospital. I'm user of the hospital with my kids, so this is one thing. Um it's a hospital that has been there for more than 100 years, and that at some point decided that they want to make uh a jump to become really the reference hospital in pediatric in south of Europe. So, really, it's it's very well centered on innovation. Okay. Um that's why there's this big connection with Git2Brain and really betting for innovation as a spin-off. Um what it's important is that really they connect the assistants with the research. So there's a lot of research there, and I think it's it needs to be connected, and really that the patients are at the center. And this is easier to say it in a paper than to do it in the reality, but other than the center, and the patients are really variated. So half of the kids are international kids. You find, you go there and and you see kids from all around the world and families, and this means that there's a lot of people working to make it happen because, for example, those families will come to Barcelona for a while. Maybe they English is not their mother tongue language, so they need someone that explains them. Obviously, they know English, but they would deserve that someone explain it in their own mother language what it's happening. And then maybe you have the brother that needs to go to school while they are so all the machinery to make it, it it means uh it means a lot of effort, but I I love to be connected with that. And in terms of science, um it gives you access to be really close to to the end user, and I don't mean only the kid, but also to family, the professionals that see the everyday, the needs. Uh so as a startup, it's very different. The fact that we have the hospital connected with us, because then our conversation are like, okay, yes, but when we will reach the end, this will be an IB. So you are not inventing that, you are really talking with people that know that.
SPEAKER_00:And actually, a spoiler alert, we do have Arno coming on to the podcast in uh uh during this season. So uh we'll hear more about the the hospital and the work that they're doing, and uh uh which I think is inspiring um for everybody. Um, Mary, just uh uh couple more questions, if we may, but where do you hope to be in a year's time? Um we know that you're kind of uh you say three years off, um, I guess human clinical trials, but um what are you hoping to achieve in the next 12 months?
SPEAKER_01:In the next 12 months? I hope to see the first uh so when you go to the clinical trial, before the clinical trial you have the preclinical regulatory. Okay, and in the preclinical regulatory you have two big parts, the rodents and the non-rodents. As I mentioned, we are in this jump of the non-rodants to rodents to non-rodents. So I hope that in one year we are injecting uh we will have already injected the first mini peaks. This means that we need to produce a lot of product because a mini peak is 35 kilos of animal. But I will love to see those experiments and really if we find that there the there's not uh side effects or huge toxicity, it will be a big jump for the project. Because in many ways, we are treating those uh peaks as a first um, not first clinical trial, but you need to organize how the needles, how so everything is very similar to when it will be in a small kit. So no how you the how you give this the product, how it needs to be stabilized. So it's very similar in terms of sizes and everything. So I will love to see my mini peaks uh already injected, and that we will be drawing really the final uh version of the clinical trial.
SPEAKER_00:Okay, well, fingers crossed um that uh that that can happen um this year. Big step forward. Um one of the uh so just one of the things that we always ask um everybody on the podcast is uh if you had a if you had a magic wand, um what would the one thing be that you could change in pediatric healthcare? I always think that I can guess, given the conversation, what it might look like. Um but uh but uh but generally get um uh surprised by the answer to this. What would be what would you do with your magic wand to help children's health?
SPEAKER_01:I will m try to make that um that when there are diseases that affect kids in general, and not only in our um we have drugs that have been developed for them. Um that we are not still recalculating by weight or other things. So I think that the population of kids deserve that drugs have been adapted or developed for them. And it's it's in many ways, and not only in in cancer, but like for infections or for so really that they have been developed for them.
SPEAKER_00:Perfect. Thank you, Mary. I'm sure that there is that we could we could go on and talk about all of the opportunities that you see in the future, but we'd love to uh uh well, hopefully we can you know follow the progress of Gate to Brain and everything that you're doing. And uh we wish you you know so much luck, and please uh you know let's let's uh let's get you back to uh to talk to us when you've uh moved further forward and we can give everyone an update of where you are.
SPEAKER_01:Sure, and it will be a pleasure to share with you the results. And the more close we are to to reach this clinical trial, the more the enthusiasm of our team.
SPEAKER_00:Perfect. Thank you so much for joining us.
SPEAKER_01:Thank you. Thanks, Mary.
SPEAKER_00:Thank you for joining us on the Not Many Adults podcast, Pioneers for Children's Health and Wellbeing. We really hope that you enjoyed that episode. You can find all the previous four seasons of the podcast's episodes wherever you listen to your podcasts. And if you, like us, are dedicated to making a difference in children's health, then we hope you'll be inspired by some of the amazing people and stories that we've had the privilege to talk to and to share. We really hope that you'll join us again, and if anybody knows of anyone that you think that we should be talking to on the podcast, then please do get in touch. Thank you so much for listening.